Ari Kellen is an angel investor who advises a number of early stage startups spanning health care and technology. One of the companies Ari Kellen advises, MyOr, combines AI and data science within an innovative digital health platform focused on baby formula. MyOr’s mission is to lead a healthcare revolution by transitioning from reactive to proactive healthcare, significantly reducing the occurrence of disease development. We predict diseases using advanced AI technologies to effectively bridge the gap between prediction and disease onset. We then employ precision nutritional interventions to optimize health outcomes, empowering individuals to proactively take charge of their well-being and lead healthier lives.
As Michael Brandwein, chief technology officer and co-founder, described it to the Jewish News Syndicate (JNS), MyOr is focused on addressing the critical needs of infants and premature babies with food sensitivities and allergies. This preventive healthcare approach also encompasses a smartphone enabled non-invasive hemoglobin test as well as digital tools for predicting eczema and food allergies (from birth).
